The Alpha L-Iduronidase pipeline drugs market research report outlays comprehensive information on the Alpha L-Iduronidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Alpha L-Iduronidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Metabolic Disorders, Central Nervous System, Musculoskeletal Disorders, and Oncology which include the indications Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Unspecified Central Nervous System Disorders, Unspecified Neurologic Disorders, Unspecified Musculoskeletal Disorders, and Unspecified Cancer. It also reviews key players involved in Alpha L-Iduronidase targeted therapeutics development with respective active and dormant or discontinued products.

The Alpha L-Iduronidase pipeline targets constitutes close to 18 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 1, 1, 6, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 2 molecule.

Alpha L-Iduronidase overview

Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I).

For a complete picture of Alpha L-Iduronidase’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.